STUDY OF RELATIONSHIP BETWEEN THE PROTEIN OXIDATION MARKERS AND ADIPOKINES IN OBESE TYPE 2 DIABETIC PATIENTS

SUKHPAL SINGH1,2, AMITA MAHAJAN2,3, JASPREET KAUR1*

1Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh, India. 2Department of Medical Lab Technology, I. K. Gujral Punjab Technical University, Jalandhar, Punjab, India. 3University School of Medical and Allied Sciences, Rayat Bahra University, Mohali, Punjab, India. Email: jaspreet_uiet@pu.ac.in

ABSTRACT

Objective: This study was done to explore the correlation if any, between obesity markers adiponectin, leptin, and protein oxidative stress (OS) status in obese with and without type 2 diabetic mellitus (T2DM) patients.

Methods: In the present study, 30 healthy subjects, 30 obese non-diabetics, and 30 obese T2DM patients were enrolled. Protein OS parameters such as advanced oxidation of protein products (AOPPs) and protein carbonyl (PC) were estimated. Serum leptin, adiponectin, and insulin levels were measured by ELISA.

Results: The AOPP, PC, leptin, leptin adiponectin ratio (LAR), insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels were significantly higher in obese non-diabetic and obese T2DM as compared to healthy control (p<0.001). However, serum adiponectin levels were significantly lower in obese non-diabetic and obese T2DM as compared to control (p<0.001). HOMA-IR and LAR both the index of IR were increased in obese non-diabetic and obese T2DM. Positive correlations were observed for AOPP with body mass index, PC in obese non-diabetic and with fasting blood glucose, postprandial blood glucose, HOMA-IR, and PC in obese T2DM. A negative correlation was found between PC and adiponectin in obese non-diabetic and obese T2DM. A significant inverse correlation was obtained between leptin and adiponectin in obese T2DM only.

Conclusion: The present study suggested that increased protein OS, hyperinsulinemia, and hyperleptinemia may lead to hypoadiponectinemia in obese with and without T2DM. Moreover, determination of protein oxidation markers can be useful for monitoring the dysregulation of adipokines and glucose metabolism in obesity and T2DM.

Keywords: Obesity, Type 2 diabetes, Adiponectin, Leptin, Protein carbonyl.

INTRODUCTION

Obesity is an epidemic and worldwide complication that represents a major health issue of the 21st century. Many studies have shown that obesity, especially visceral obesity is linked to chronic low-grade inflammation in hypertrophied adipose tissue that leads to initiation and progression of metabolic disorders such as dyslipidemia, hypertension, atherosclerosis, insulin resistance (IR), and type 2 diabetic mellitus (T2DM) [1]. Adipose tissue is not only a major source of energy for the human body but also inert storage reservoir for lipids [2]. The term adipokines can be defined as a biologically active substance released by adipose tissue [3]. It is now considered as a largest endocrine organ of the body that helps in the regulation of glucose and lipid metabolism, insulin sensitivity and secretion, inflammatory process, appetite, satiety, energy expenditure, endothelial function, blood pressure, and neuroendocrine regulation [4]. Most of the adipokines are proinflammatory and less the number of anti-inflammatory adipokines [5,6]. In contrast, leptin is proinflammatory, a product of obese (ob) gene is a 16-kDa circulating protein hormone produced by adipocytes. It is an adipokines and a key molecule that regulates food intake and body weight [12]. The level of plasma leptin is directly proportional to the mass of body fat [13]. It also plays an important role in the regulation of body metabolism, energy homeostasis, and neuroendocrine function [14]. It acts by binding to circulating receptors, triggers Janus kinase, and induces signal transducer and activator of transcription pathway [15]. Increased leptin directly modulates pancreatic beta cells functions and indirectly through central neural pathways leading to progression of IR and T2DM [4,16]. Dysregulation of adipokines occurs through the generation of reactive oxygen species (ROS) in adipose tissue induces systemic oxidative stress (OS) in obesity. Moreover, the following OS is, directly and indirectly, related to the pathogenesis of obesity-associated IR [17].

Advanced oxidation of protein products (AOPPs) are ROS generated chlorinated oxidants, mainly hypochlorous acid and chloramines, derived by myeloperoxidase in activated neutrophils [18]. They are defined as dityrosine-containing cross-linked protein products and are a reliable marker to measure the degree of protein oxidation [19,20], whereas determination of plasma protein carbonyl (PC) is most stable and commonly used as an early marker of protein oxidation [21,22]. Increased level of carbonyl content has been found in several diseases such as rheumatoid arthritis, Alzheimer’s disease, diabetic mellitus, and muscle damage due to strenuous exercise. With the binding of metal cations to protein and further attack of ROS, especially hydrogen peroxide and oxygen species modify amino acid lead to the formation...
of carbonyls [23]. Increased level of AOPP and PC has been found in obesity and diabetes [20,23].

From extensive literature study, we found that there is a lack of data to clearly explain the relationship between circulating metabolic homeostasis adipokines and protein OS parameters in North India population specifically from Chandigarh region and its surroundings. This study evaluates the comparative and relative relationship between leptin, adiponectin, leptin adiponectin ratio (LAR), insulin, homeostasis model assessment of IR (HOMA-IR), and protein OS markers in obese subjects as well as in obese T2DM patients.

MATERIALS AND METHODS

This case-control study included 90 subjects, of which 30 healthy controls (body mass index [BMI] ≤25 kg/m²), 30 obese non-diabetics (BMI ≥30 kg/m²), and 30 obese T2DM patients (BMI ≥30 kg/m²) were enrolled.

Anthropometric parameters and subject selection

The anthropometric parameters included weight and height measurements for determination of BMI. Each subject was provided a questionnaire for information about age, sex, height, weight, smoking status, and alcohol consumption. Care was taken to select healthy control subjects with BMI (≤25 kg/m²) and had no family history of diabetes mellitus. The inclusion criteria for age in all groups were 30–50 years. For diabetic patients duration of diabetes was at least 5 years or more, fasting glucose ≥126 mg/dl and level of glycated hemoglobin (HbA1C) ≥6.5%. The criteria for selection of type 2 diabetic patients were in accordance with the World Health Organization, and all were under diabetic treatment with oral hypoglycemic drugs. This study excluded the patients taking antioxidants supplements, anti-inflammatory drugs, antidiabetes therapies, inflammatory or malignant disease, history of hospitalization in preceding 6 months, pregnant and lactating women, Type 1 diabetic patients, and exogenous insulin. The study was approved by the Government Multispecialty hospital, Chandigarh (MS-II-2015/4631), India. All the participants were informed about the objectives of the study and written informed consent was obtained from all subjects involved in this study.

Sample collection

Venous peripheral blood sample of each subject was collected after 10–12 h of overnight fasting. Samples were collected into plain sterile and ethylenediaminetetraacetic acid (EDTA) anticoagulant Vacutainers tubes. For estimation of HbA1C whole blood collected in EDTA was used. Plasma samples were used for the measurement of AOPP and PC. The fasting serum samples were used for the measurement of fasting blood glucose (FBG), lipid profile, insulin, leptin, and adiponectin. Serum and plasma were stored at −80°C until further use.

Biochemical measurements

HbA1C was measured using commercially available kits (Erba Diagnostics Mannheim, Germany) by ion exchange resin method. Serum leptin and insulin level were measured quantitatively using solid phase enzyme-linked immunosorbent assay ELISA kit (DRG International, Inc., USA) and serum adiponectin was measured by human Acpro 30 ELISA kit (Ray Biotech Inc., USA). AOPP level was measured by the spectrophotometric method of Witko-Sarsat et al. 1998 [16]. PC level was measured by the method of Reznick and Packer 1994 [21]. Blood glucose, total cholesterol (TC), triglycerides (TG), and high-density lipoprotein (HDL) cholesterol were measured by Erba Transasia diagnostic kits. Low-density lipoprotein (LDL) cholesterol and very LDL (VLDL) cholesterol were calculated indirectly by Friedewald's formula [24]. IR was calculated by the HOMA-IR [25].

HOMA-IR = Fasting insulin (µU/ml) × Fasting glucose (mmol/L)/22.5

Table 1: Clinical and demographical details of the subjects in groups

| Parameters                  | Healthy control | Obese non-diabetic | Obese T2DM |
|-----------------------------|-----------------|--------------------|------------|
|                             | BMI≤25          | BMI≥30             | BMI≥30     |
| n                           | 30              | 30                 | 30         |
| Age (years)                 | 40.23±6.89      | 41.30±6.48         | 47.40±3.50 |
| Gender (male/female)        | 18/12           | 20/10              | 15/15      |
| BMI (kg/m²)                 | 22.67±2.04      | 32.63±2.73         | 32.83±2.56 |
| p                           | <0.504*         | <0.001*            | <0.001*    |
| FBG (mmol/L)                | 4.47±0.20       | 4.64±0.35          | 10.47±0.77 |
| p                           | <0.026*         | <0.001*            | <0.001*    |
| PPBG (mmol/L)               | 6.37±0.71       | 6.75±0.69          | 14.91±2.54 |
| p                           | <0.617*         | <0.001*            | <0.001*    |
| HbA1c (%)                   | 4.54±0.36       | 4.60±0.38          | 8.92±0.96  |
| p                           | <0.908*         | <0.001*            | <0.001*    |
| Cholesterol (mg/dl)         | 15.67±2.25      | 18.54±2.45         | 19.17±2.17 |
| p                           | <0.001*         | <0.001*            | <0.001*    |
| Triglycerides (mg/dl)       | 110.37±32.31    | 167.01±45.00       | 246.89±48.55 |
| p                           | <0.001*         | <0.001*            | <0.001*    |
| HDL-cholesterol (mg/dl)     | 51.23±5.32      | 48.34±5.16         | 39.85±4.42 |
| p                           | <0.069          | <0.001*            | <0.001*    |
| LDL-cholesterol (mg/dl)     | 83.17±19.40     | 102.83±31.63       | 105.94±32.57 |
| p                           | <0.011*         | <0.003*            | <0.075*    |
| VLDL-cholesterol (mg/dl)    | 22.07±6.46      | 33.40±9.00         | 49.38±9.71 |
| p                           | <0.001*         | <0.001*            | <0.001*    |
| Insulin (µIU/ml)            | 6.78±2.01       | 13.17±4.31         | 13.58±3.85 |
| p                           | <0.001*         | <0.001*            | <0.001*    |
| HOMA-IR                     | 1.35±0.42       | 2.74±0.99          | 6.17±1.72  |
| p                           | <0.001*         | <0.001*            | <0.001*    |

Data are represented as means±SD. p<0.05 statistically significant. *p significance versus Healthy control, **p significance versus obese non diabetic BMI. Body mass index, FBG: Fasting blood glucose, PPBG: Post-prandial blood glucose, T2DM: Type 2 diabetes mellitus, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, HOMA-IR: Homeostasis model assessment of insulin, HbA1C: Glycated hemoglobin, SD: Standard deviation.
Results

The demographic and clinical parameters studied in all groups were classified by BMI

In Table 1, FBG, TC, TG, LDL-cholesterol, VLDL-cholesterol, insulin, and HOMA-IR were found to be with significantly higher in obese non-diabetic and obese T2DM groups as compared to healthy control (p<0.05 or p<0.001). Age, postprandial blood glucose (PPBG), HDL-cholesterol, and HbA1c significantly higher in obese T2DM as compared to obese non-diabetic and healthy control (p<0.001). In Table 2, leptin showed significantly increased whereas adiponectin significantly decreased in both obese non-diabetic and obese T2DM as compared to healthy control (p<0.001). LAR, AOPP, and PC significantly higher in obese non-diabetic and obese T2DM groups as compared to healthy control (p<0.001).

Correlation analysis studied among different parameters in all groups

In healthy control, AOPP showed positive correlation with HbA1c (r=0.411, p<0.024), between insulin and HOMA-IR (r=0.977, p<0.001). LAR showed positive correlation with leptin (r=0.914, p<0.001) but negative correlation with adiponectin (r=−0.547, p<0.002) and HbA1c (r=−0.383, p<0.037) (Table 3).

In obese non-diabetic, a positive correlation was found between age and PPBG (r=0.381, p<0.038). BMI was positively correlated with LAR

Table 2: Adipokines and oxidative stress parameters details of the subjects in groups

| Parameters                  | Healthy control | Obese non-diabetic | Obese T2DM |
|-----------------------------|-----------------|--------------------|------------|
| Leptin (ng/ml)              | 6.82 ± 3.59     | 25.67 ± 8.13       | 26.89 ± 4.45 |
| p                           | <0.001*         | <0.001*, <0.544**  |
| Adiponectin (ng/ml)         | 15.53 ± 3.42    | 8.93 ± 1.77        | 7.56 ± 1.66 |
| p                           | <0.001*         | <0.001*, <0.079**  |
| Leptin/adiponectin ratio    | 0.47 ± 0.27     | 3.02 ± 1.38        | 3.81 ± 1.38 |
| p                           | <0.001*         | <0.001*, <0.007**  |
| AOPP (µmol/l)               | 165.35 ± 41.79  | 208.84 ± 42.32     | 302.67 ± 57.64 |
| p                           | <0.001*         | <0.001*, <0.001**  |
| PC (nmol/mg protein)        | 0.72 ± 0.07     | 0.98 ± 0.22        | 1.46 ± 0.24 |
| p                           | <0.001*         | <0.001*, <0.001**  |

Data are represented as mean ± SD. p<0.05 statistically significant. *p, significance versus healthy control, **p, significance versus obese non-diabetic. AOPP: Advanced oxidation of protein products; PC: Protein carbonyl, T2DM: Type 2 diabetic mellitus

Table 3: Spearman’s correlation among measured parameters in healthy control

| Parameters   | Age | BMI | FBG | PPBG | HbA1c | Insulin | HOMA-IR | Leptin | Adiponectin | LAR | AOPP |
|--------------|-----|-----|-----|------|-------|---------|---------|--------|-------------|-----|-------|
| BMI r        | 0.168 | 1.000 |     |      |       |         |         |        |             |     |       |
| p            | 0.375 |         |     |      |       |         |         |        |             |     |       |
| FBG r        | 0.295 | -0.131 | 1.000 |     |      |         |         |        |             |     |       |
| p            | 0.113 | 0.491 |       |     |      |         |         |        |             |     |       |
| PPBG r       | -0.022 | -0.109 | 0.173 | 1.000 |     |         |         |        |             |     |       |
| p            | 0.908 | 0.567 | 0.361 |       |     |         |         |        |             |     |       |
| HbA1c r      | 0.230 | -0.237 | 0.099 | 0.240 | 1.000 |         |         |        |             |     |       |
| p            | 0.222 | 0.207 | 0.602 | 0.200 |       |         |         |        |             |     |       |
| Insulin r    | 0.053 | -0.176 | 0.050 | 0.118 | 0.120 | 1.000 |         |        |             |     |       |
| p            | 0.780 | 0.352 | 0.794 | 0.536 | 0.526 |       |         |        |             |     |       |
| HOMA-IR r    | 0.120 | -0.115 | 0.196 | 0.150 | 0.133 | 0.977** | 1.000 |         |             |     |       |
| p            | 0.528 | 0.545 | 0.300 | 0.428 | 0.484 | 0.001 |       |        |             |     |       |
| Leptin r     | 0.042 | 0.121 | -0.112 | 0.219 | -0.350 | 0.073 | 0.072 | 1.000 |             |     |       |
| p            | 0.826 | 0.523 | 0.555 | 0.244 | 0.058 | 0.700 | 0.707 |       |             |     |       |
| Adiponectin r| -0.042 | -0.163 | 0.081 | 0.205 | 0.107 | 0.125 | -0.219 | 1.000 |             |     |       |
| p            | 0.824 | 0.389 | 0.372 | 0.670 | 0.276 | 0.574 | 0.510 | 0.245 |             |     |       |
| LAR r        | 0.070 | 0.228 | -0.130 | 0.186 | -0.383* | 0.019 | 0.021 | 0.914** | -0.547** | 1.000 |
| p            | 0.712 | 0.226 | 0.492 | 0.325 | 0.037 | 0.921 | 0.194 | 0.001 | 0.002 |       |
| AOPP r       | -0.043 | -0.232 | 0.091 | 0.411* | 0.180 | 0.204 | -0.069 | 0.265 | -0.189 | 1.000 |
| p            | 0.823 | 0.216 | 0.312 | 0.634 | 0.024 | 0.341 | 0.281 | 0.717 | 0.157 | 0.316 |
| PC r         | 0.082 | -0.221 | 0.209 | 0.007 | 0.117 | 0.069 | 0.080 | -0.009 | -0.126 | 0.021 | 0.170 |
| p            | 0.668 | 0.241 | 0.268 | 0.969 | 0.536 | 0.719 | 0.676 | 0.962 | 0.509 | 0.914 | 0.370 |

*Correlation is significant at the 0.05 level (two-tailed). **Correlation is significant at the 0.01 level (two-tailed). BMI: Body mass index, FBG: Fasting blood glucose, PPBG: Postprandial blood glucose, HbA1c: Glycated hemoglobin, HOMA-IR: Homeostasis model assessment of insulin resistance, LAR: Leptin/adiponectin ratio, AOPP: Advanced oxidation of protein products, PC: Protein carbonyl.
In obese T2DM, FBG positive correlation found among PPBG, HbA1c, insulin, and HOMA-IR (r=0.502, p<0.005; r=0.373, p=0.042; r=0.437, p=0.016; and r=0.670, p=0.001), respectively. HOMA-IR positive correlation found among PPBG, HbA1c, and insulin (r=0.528, p<0.001; r=0.536, p=0.002; and r=0.867, p=0.001), respectively. A negative correlation between leptin and adiponectin (r=-0.402, p=0.028). LAR positively correlated with leptin (r=0.731, p<0.001) but negatively correlated with adiponectin (r=-0.879, p<0.001). AOPP positively correlated with FBG, PPBG, HOMA-IR, and PC (r=0.385, p=0.036; r=0.422, p=0.020; r=0.497, p=0.005; and r=0.482, p=0.007) whereas PC negatively correlated with adiponectin (r=-0.371, p=0.043) (Table 4).

**DISCUSSION**

This study was done to examine protein oxidative markers (AOPP, PC) and major metabolic homeostasis markers (adiponectin, leptin, and LAR) in obese subjects with and without T2DM. Obese T2DM and obese non-diabetic had a significantly lower level of serum adiponectin as compared to lean T2DM and healthy control, respectively. Serum adiponectin level was decreased in obese subjects with and without diabetes, a similar trend was also seen in this study [26,27]. Decreased level of adiponectin has been strongly associated with IR and inflammation was seen as the main cause of the link between obesity and T2DM [28]. Adiponectin was negatively correlated with leptin in obese T2DM which is in accordance with previous reports [29]. This was due to increased HOMA-IR and leptin level and decreases adiponectin level which strongly predicts IR [30].

In contrast to adiponectin, leptin levels increase in obesity which is proportional to the degree of adiposity [13,31]. In this study, serum leptin and LAR were higher in both obese T2DM and obese non-diabetic patients with respect to healthy control. From this study, we observed that serum leptin and LAR were higher in obese patients whether obese patients were diabetic or not which is consistent with a previous study [16,32]. An earlier report showed that serum leptin was negatively correlated with serum adiponectin; this study also showed similar trends in obese T2DM patients [33]. As reported by Al-Hamodi et al. [13], an inverse association between leptin and adiponectin was observed which highlight the recent findings that indicated that the two adipokines interact with each other in the inflammation of T2DM risks. Both leptin and adiponectin play an important role in the maintenance of metabolic homeostasis and fat accumulation in adipose tissue [9]. In central obesity, disturbance of their levels leads to increase appetite and reduced energy expenditure results in IR by the accumulation of fat in adipose tissue [1].

In this study, HOMA-IR and LAR both indexes of IR were increased in obese non-diabetic and obese T2DM as compared to healthy control. As suggested by Satoh et al. [34], Kotani et al. [35], and LAR represented as a potential marker of an atherogenic index in obese type 2 diabetic patients. LAR is the most reliable marker of IR than HOMA-IR to leptin or adiponectin alone in obesity with and without type 2 diabetes [30]. It is also reported LAR to be associated with central obesity and metabolic syndrome subjects [35]. In this study, we observed LAR be positively correlated with BMI in obese non-

**Table 4: Spearman’s correlation among measured parameters in obese nondiabetic**

| Parameters | Age | BMI | FBG | PPBG | HbA1c | Insulin | HOMA-IR | Leptin | Adiponectin | LAR | AOPP |
|------------|-----|-----|-----|------|-------|---------|---------|--------|-------------|-----|-------|
| BMI        | -0.204 | 1.000 |
| r          | p 0.279 |   |
| FBG        | -0.152 | 0.251 | 1.000 |
| r          | p 0.422 | 0.180 |   |
| PPBG       | 0.381* | 0.012 | -0.109 | 1.000 |
| r          | p 0.038 | 0.949 | 0.565 |   |
| HbA1c      | -0.187 | 0.217 | 0.149 | 0.307 | 1.000 |
| r          | p 0.323 | 0.249 | 0.433 | 0.098 |   |
| Insulin    | 0.120 | 0.143 | 0.252 | 0.282 | 0.051 | 1.000 |
| r          | p 0.527 | 0.452 | 0.180 | 0.131 | 0.787 |   |
| HOMA-IR    | 0.054 | 0.177 | 0.429* | 0.254 | 0.106 | 0.968** | 1.000 |
| r          | p 0.776 | 0.350 | 0.018 | 0.176 | 0.577 | 0.001 |   |
| Leptin     | 0.095 | 0.287 | 0.185 | -0.173 | 0.109 | 0.187 | 0.183 | 1.000 |
| r          | p 0.616 | 0.124 | 0.328 | 0.361 | 0.565 | 0.322 | 0.334 |   |
| Adiponectin| -0.127 | 0.018 | -0.049 | -0.287 | -0.319 | -0.078 | -0.106 | -0.116 | 1.000 |
| r          | p 0.504 | 0.925 | 0.797 | 0.124 | 0.086 | 0.681 | 0.577 | 0.541 |   |
| LAR        | 0.064 | 0.375* | 0.283 | -0.075 | 0.203 | 0.295 | 0.321 | 0.909** | -0.384* | 1.000 |
| r          | p 0.736 | 0.041 | 0.130 | 0.694 | 0.283 | 0.113 | 0.084 | 0.001 | 0.036 |   |
| AOPP       | -0.006 | 0.429* | -0.059 | 0.151 | 0.165 | -0.151 | -0.105 | 0.025 | -0.312 | 0.196 | 1.000 |
| r          | p 0.973 | 0.018 | 0.756 | 0.427 | 0.384 | 0.426 | 0.582 | 0.897 | 0.093 | 0.300 |   |
| PC         | -0.034 | 0.335 | -0.084 | 0.013 | 0.102 | -0.191 | -0.159 | -0.181 | -0.412* | -0.015 | 0.702** |
| r          | p 0.857 | 0.071 | 0.661 | 0.945 | 0.593 | 0.312 | 0.403 | 0.340 | 0.024 | 0.936 | 0.001 |

*Correlation is significant at the 0.05 level (two-tailed). **Correlation is significant at the 0.01 level (two-tailed). BMI: Body mass index, FBG: Fasting blood glucose, PPBG: Post-prandial blood glucose, HbA1c: Glycated hemoglobin, HOMA-IR: Homeostasis model assessment of insulin resistance, LAR: Leptin/adiponectin ratio, AOPP: Advanced oxidation of protein products, PC: Protein carbonyl.
Table 5: Spearman’s correlation among measured parameters in obese type 2 diabetes mellitus

| Parameters | Age | BMI | FBG | PPBG | HbA1c | Insulin | HOMA-IR | Leptin | Adiponectin | LAR | AOPP |
|-----------|-----|-----|-----|------|-------|---------|---------|--------|-------------|-----|------|
| BMI       |     | r  |     | p  |      |         |         |        |             |     |      |
| r         | -0.075 | 1.00 |
| p         | 0.695 |      |
| PPBG      |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.186 | 0.142 | 1.00 |
| p         | 0.325 | 0.453 |
| HbA1c     |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.077 | -0.024 | 0.502** | 1.00 |
| p         | 0.685 | 0.899 | 0.005 |
| Leptin    |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.204 | 0.114 | 0.373* | 0.330 | 1.000 |
| p         | 0.279 | 0.549 | 0.042 | 0.075 |
| Insulin   |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.242 | 0.071 | 0.437* | 0.279 | 0.527** | 1.000 |
| p         | 0.197 | 0.711 | 0.016 | 0.136 | 0.003 |
| HOMA-IR   |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.276 | 0.073 | 0.670** | 0.528** | 0.536** | 0.867** | 1.000 |
| p         | 0.139 | 0.702 | 0.001 | 0.003 | 0.002 | 0.001 |
| Leptin    |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | 0.191 | 0.062 | -0.070 | -0.138 | -0.032 | -0.209 | -0.216 | 1.000 |
| p         | 0.313 | 0.744 | 0.715 | 0.469 | 0.865 | 0.268 | 0.252 |
| Adiponectin|     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.151 | -0.138 | 0.102 | 0.201 | -0.190 | -0.021 | 0.037 | -0.402* | 1.000 |
| p         | 0.427 | 0.467 | 0.593 | 0.287 | 0.315 | 0.914 | 0.848 | 0.028 |
| LAR       |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | 0.126 | 0.104 | -0.106 | -0.209 | 0.170 | -0.056 | -0.111 | 0.731** | -0.879** | 1.000 |
| p         | 0.509 | 0.586 | 0.577 | 0.268 | 0.369 | 0.768 | 0.559 | 0.001 | 0.001 |
| AOPP      |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.073 | 0.351 | 0.385* | 0.422* | 0.317 | 0.321 | 0.497** | -0.201 | -0.045 | -0.029 | 1.000 |
| p         | 0.703 | 0.057 | 0.036 | 0.020 | 0.088 | 0.084 | 0.005 | 0.207 | 0.013 | 0.090 |
| Pc        |     | r  |     | p  |       |         |         |        |             |     |      |
| r         | -0.045 | 0.069 | 0.142 | 0.105 | -0.090 | 0.227 | 0.289 | -0.336 | -0.371* | 0.084 | 0.482** |
| p         | 0.813 | 0.716 | 0.454 | 0.580 | 0.635 | 0.228 | 0.121 | 0.070 | 0.043 | 0.658 | 0.007 |

*pCorrelation is significant at the 0.05 level (two-tailed). **Correlation is significant at the 0.01 level (two-tailed). BMI: Body mass index, FBG: Fasting blood glucose, PPBG: Post-prandial blood glucose, HbA1c: Glycated hemoglobin, HOMA-IR: Homeostasis model assessment of insulin resistance, LAR: Leptin/adiponectin ratio, AOPP: Advanced oxidation of protein products, PC: Protein carbonyl.

It is well studied that obesity induces OS that plays an important role in the pathogenesis of diabetes. AOPPs had a significantly higher level in obese T2DM and obese non-diabetic in contrast to lean healthy control. AOPPs increased level is reported to be associated with obesity and diabetes [20,37]. Increased AOPPs may be an independent risk factor for coronary artery disease [19] and early marker of endothelial dysfunction in T2DM patients [38]. In this study, AOPP positively correlated with BMI, PC in obese non-diabetic subjects and with FBG, PPBG, HOMA-IR, and PC in obese T2DM which was in accordance with previous studies [39]. Li et al [40] also reported that at 32–36 weeks gestational diabetes mellitus showed a significant relationship between AOPP and FBG level compared to normal pregnancies. Increase in levels of AOPP and PC may lead to development in the growth of diabetic complications and cardiovascular diseases.

In this study, we found a significant increase in PC level in obese T2DM patients as compared to obese non-diabetic and healthy control which was in accordance with previous reports [41,42]. According to Frohner et al. [43], human obesity OS is linked to protein carbonylation which is directly correlated to adiposity and serum free fatty acids that may eventually lead to the development of IR. Studies have shown that in aging proteome accumulated OS-related post-translational modification including glycation, lipid peroxidation, and carbonylation observed in chronic inflammation, metabolic syndrome, and diabetes [44]. This study found an inverse correlation with increased PC level and decreased adiponectin in obese non-diabetic and obese T2DM which is in accordance with previous studies [45]. Therefore, this study supports the relation of obesity between protein OS markers and circulating adipokines.

CONCLUSION

Present the study suggests that an increase in levels of leptin, insulin, AOPP, and PC in obese non-diabetic subjects and obese T2DM patients play an important role in reducing the level of adiponectin. A significant increase in the level of HOMA-IR and LAR in obese suggests in the development of T2DM and IR. Moreover, obese subjects have increased OS that may contribute to the dysregulation of adipokines and altered glucose metabolism.

ACKNOWLEDGMENT

Authors are grateful to UIET (Branch Biotechnology), Panjab University, Chandigarh, India, and I. K. Gujral Punjab Technical University, Jalandhar, Punjab, India, for providing infrastructure and facilities to carry out this research work.

DISCLOSURE STATEMENT

The authors declare that there are no conflicts of interest.

REFERENCES

1. Matsuda M, Shimomura I. Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 2013;7:e330-41.
2. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006;83:4615–4658.

3. Nakamishi S, Yamane K, Kaneki N, Nojima H, Okubo M, Kohno N, et al. A protective effect of adiponectin against oxidative stress in Japanese Americans: The association between adiponectin or leptin and urinary isoprostane. Metabolism 2005;54:194-9.

4. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism 2015;64:133–45.

5. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-4.

6. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013;17:185-96.

7. Aleidi S, Issa A, Bustanji H, Khalil M, Bustanji Y. Adiponectin serum levels correlate with insulin resistance in Type 2 diabetic patients. Saudi Pharm J 2015;23:250-6.

8. Shibata R, Murohara T, Ouchi N. Protective role of adiponectin in cardiovascular disease. Curr Med Chem 2012;19:5459-66.

9. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 2016;23:770-84.

10. Saad EA, Habib SA, Refai WA, Elfayoumy AA. Malondialdehyde, adiponectin, nitric oxide, C reactive protein, tumor necrosis factor-alpha and insulin resistance relationships and inter-relationships in Type 2 diabetes early stage is metformin alone adequate in this stage. Int J Pharm Pharm Sci 2017;9:176-81.

11. Yamauchi T, Kanon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipopathea and obesity. Nat Med 2001;7:941-6.

12. Ikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and inflammation. Curr Immunol Rev 2008;4:70-9.

13. Al-Hamoudi Z, Al-Haboty M, Al-Meeri A. Saiif-Al R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and Type 2 diabetes mellitus. Diabetes Metab Syndr 2014;6:49-6.

14. Farooqi IS, O'Rahilly S. Leptin: A pivotal regulator of human energy balance. Nat Rev Endocrinol 2009;5:461-74.

15. Chen VC, Chen CH, Chiu YH, Lin TY, Li FC, Lu ML, et al. Leptin-to-adiponectin ratio for metabolic syndrome in patients with schizophrenia. Psychoneuroendocrinology 2018;94:434-41.

16. Hamed EA, Zakary MM, Ahmed NS, Gamal RM. Circulating leptin and insulin in obese patients with and without Type 2 diabetes mellitus: Relation to ghrelin and oxidative stress. Diabetes Res Clin Pract 2011;94:343-41.

17. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2012;13:3117-32.

18. Vitkova-Sarat S, Friedlander M, Nguyen Khoa T, Capellière-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products in women with and without gestational diabetes mellitus. Diabetes Metab Syndr 2007;7:188-92.

19. Reznick AZ, Packer L. Oxygen radicals in biological systems Part C. Methods Enzymol 1994;233:357-63.

20. Gelissen R, Genc H, Kayali R, Oncul M, Benian A, Guralp O, et al. Protein oxidation markers in women with and without gestational diabetes mellitus: A possible relation with paraoxonase activity. Diabetes Res Clin Pract 2011;94:404-9.

21. Atabek ME, Keskin M, Yazici C, Kendirci M, Hatipoglu N, Koko E, et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr 2006;165:753-6.

22. Frohnert BI, Sinaiko AR, Serrot FJ, Foncea RE, Moran A, Ikramuddin S, et al. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 2008;41:943-9.

23. Koçak H, Oner-Iyidoğan Y, Gürdöl F, Oner P, Süzme R, Esin D, et al. Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in Type 2 diabetes patients without albuminuria. J Diabetes 2014;6:417-26.

24. Gupta V, Mishra S, Mishra S, Kumar S, Gupta V. Association of leptin: Adiponectin ratio and metabolic risk markers in postmenopausal women. Hum Publ Health 2018;196:63-7.

25. Krzystek-Korpacka M, Patryn E, Boehm D, Berdowska I, Zielinski B, Bojarski J, et al. Increased adiponectin or leptin and Type 2 diabetes mellitus. Diabetes Care 2004;27:2488-90.

26. Kotani K, Nakane S, Saiga K, Kurozawa Y. Leptin: Adiponectin ratio as an atherosclerotic index in patients with Type 2 diabetes: Relationship of the index to carotid intima-media thickness. Diabetologia 2005;48:2684-6.

27. Bollineni RC, Fedorova M, Blüher M, Hoffmann R. Carbonylated adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and Type 2 diabetes mellitus. Diabetol Metab Syndr 2014;6:99.

28. Fernández-Real JM, Botas-Cervero P, López-Bermejo A, Casamitjana R, Funahashi T, Delgado E, et al. Adiponectin is independently associated with glycosylated haemoglobin. Eur J Endocrinol 2004;150:201-5.

29. Inoue M, Yano M, Yamakado M, Maehata E, Suzuki A. Relationship of leptin to fat distribution, oxidative stress and inflammation in Japanese Americans: The association between adiponectin or leptin and Type 2 diabetes mellitus. J Nutr Biochem 2006;17:461S-465S.